The application of immune-based therapies to augment the anti-tumor immune response followingautologous and allogeneic BMT has dramatically, increased over the past several years. Reconstitution ofthe immune system following BMT, graft-versus-host disease and post-grafting immunosuppression maymodify any immunotherapeutic approach. The need to carefully evaluate, and monitor the immune responsein this setting has become increasingly apparent. The principle objective of the Immunological MonitoringCore (IMC) is to provide state of the art immunologic techniques to characterize and quantify the humanimmune response in support of the five research projects of this BMT program project. While there is greatdiversity in the therapeutic modalities being evaluated, most areas strongly overlap with regard to analysisand characterization of the immune response. A wide-variety of techniques that enumerate and characterizeantigen-specific T cells, assess their functional behavior ex vivo and evaluate the diversity of the T cellresponse are currently available. Specifically, the goals of the IMC are: .1. provide technical expertise in monitoring and characterizing the immune response2. establish standard operating procedures and quality control measures for all immunological assays3. provide technical support to identify or develop assays specific for all project investigators4. serve as a repository peripheral blood lymphocytes collected from the patients on the clinical trials
Showing the most recent 10 out of 456 publications
